Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy-Reference-Cited by-同舟云学术

Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy

Published:2022-04 Issue:2 Volume:7 Page:100463
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Grande E.,Alonso-Gordoa T.,Reig O.,Esteban E.,Castellano D.,Garcia-del-Muro X.,Mendez M.J.,García-Donas J.,González Rodríguez M.,Arranz-Arija J.A.,Lopez-Criado P.,Molina-Cerrillo J.,Mellado B.,Alvarez-Fernandez C.,De Velasco G.,Cuéllar-Rivas M.A.,Rodríguez-Alonso R.M.,Rodríguez-Moreno J.F.,Suarez-Rodriguez C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer-Version 4.2021,2021

2. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2019

3. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Powles;Ann Oncol,2021

4. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

5. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy;Kidney Cancer;2024-08-02

2. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2024-08

3. Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review;Cancers;2024-07-20

4. Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor;Cancer;2024-04-02

5. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review;Cancer Treatment Reviews;2024-01